A new study has identified autoantibodies targeting CD320, the cellular receptor responsible for transporting vitamin B12 into cells, in a subset of people with idiopathic myelopathy—a group of spinal cord disorders whose causes remain unexplained after standard diagnostic testing. The findings suggest that an immune response against the vitamin B12 transport system may contribute to neurological disease in some patients, particularly those whose symptoms and imaging resemble subacute combined degeneration, a classic pattern of spinal cord injury associated with severe B12 deficiency.
The study, published in JAMA Neurology, examined whether previously unrecognized autoantibodies could help explain cases of myelopathy that do not fit established infectious, inflammatory, structural, metabolic, or genetic diagnoses. Myelopathy can produce weakness, sensory changes, impaired coordination, stiffness, gait difficulties, and disturbances in bladder or bowel function. Although clinicians routinely investigate vitamin B12 deficiency in such patients, conventional blood tests do not always reveal whether the nervous system is receiving enough of the vitamin to maintain normal cellular metabolism.
Vitamin B12, also known as cobalamin, is essential for several biochemical reactions that support the nervous system. It functions as a cofactor for methionine synthase, an enzyme involved in methylation reactions and the production of molecules needed for DNA synthesis and myelin maintenance. It is also required by methylmalonyl-CoA mutase, which helps process certain fatty acids and amino acids. When B12-dependent pathways fail, abnormal metabolites can accumulate, methylation can become impaired, and the protective myelin surrounding nerve fibers may deteriorate. In the spinal cord, this damage can preferentially affect the posterior and lateral columns, producing the characteristic pattern known as subacute combined degeneration.
For B12 to reach the interior of a cell, it must pass through a specialized transport pathway. After B12 circulates in the bloodstream bound to carrier proteins, cells internalize the vitamin through receptors and intracellular trafficking mechanisms. CD320, also called the transcobalamin receptor, recognizes transcobalamin-bound B12 and helps bring the vitamin into cells through receptor-mediated uptake. Once internalized, B12 is processed and delivered to the cellular compartments where its cofactor functions are required. Antibodies that recognize CD320 could theoretically interfere with this process, although the study’s findings do not by themselves establish that the antibodies directly cause neurological injury.
The investigators used a case-control design to compare individuals with idiopathic myelopathy with control participants and searched for antibodies directed against CD320. The study detected these autoantibodies in a portion of patients with unexplained spinal cord disease. The association appeared particularly relevant among individuals whose clinical presentation resembled subacute combined degeneration, raising the possibility that a functional B12 deficiency may exist within the central nervous system even when routine systemic measurements do not provide a clear explanation.
A central nervous system-restricted deficiency would be difficult to detect with standard screening alone. Blood concentrations of B12 may be influenced by dietary intake, supplementation, binding proteins, liver function, kidney function, and other medical conditions. In addition, total circulating B12 does not necessarily indicate how efficiently the vitamin is transported into particular tissues. More sensitive metabolic tests can provide indirect evidence that B12-dependent reactions are failing. Measurements of methylmalonic acid and homocysteine, for example, may reveal impaired B12 metabolism, although their interpretation requires clinical context and can be affected by other conditions.
The study therefore points toward a possible two-stage diagnostic approach for selected patients with unexplained myelopathy. First, clinicians could screen for antibodies against CD320 when the presentation suggests impaired B12-dependent spinal cord metabolism. A positive antibody result could then be followed by metabolic testing designed to determine whether the central nervous system is functionally deficient in B12. This strategy could be particularly relevant when patients have neurological findings or magnetic resonance imaging patterns suggestive of subacute combined degeneration but lack a straightforward explanation based on serum B12 levels or more common causes of myelopathy.
The findings may also help explain why some patients with idiopathic myelopathy remain undiagnosed despite extensive testing. Autoimmune diseases do not always arise from antibodies that attack a tissue directly. In some disorders, antibodies disrupt receptors, transporters, enzymes, or other components of cellular communication. An antibody directed at CD320 could represent such a mechanism by interfering with nutrient delivery rather than causing immediate, visible destruction of neurons. However, the presence of an antibody is not proof of pathogenicity. Further work will be needed to determine whether anti-CD320 antibodies block receptor activity, accelerate receptor removal, alter intracellular B12 trafficking, or simply mark another immune process associated with the disease.
The results also raise questions about treatment. If anti-CD320 antibodies are shown to impair B12 transport, conventional vitamin supplementation might not be sufficient for every affected patient, depending on the severity and location of the transport defect. Physicians would need evidence from functional studies and clinical trials before considering immune-directed therapies, intensified B12 replacement, or combinations of both. At present, the study supports additional diagnostic investigation rather than a definitive treatment protocol. Patients with suspected B12-related neurological disease should be evaluated by clinicians who can integrate symptoms, imaging, nutritional history, metabolic markers, antibody testing, and alternative diagnoses.
The researchers emphasize that the findings apply to a subset of people with idiopathic myelopathy, not to all cases of spinal cord disease. Myelopathy can result from compression, inflammation, infection, toxic exposure, vascular injury, inherited disorders, malignancy, nutritional deficiency, or other autoimmune conditions. Anti-CD320 testing will require validation in larger and more diverse populations before its accuracy, clinical thresholds, and predictive value are known. Nevertheless, the discovery offers a new biological link between autoimmunity and B12-dependent nerve metabolism and suggests that some apparently unexplained spinal cord disorders may reflect a hidden failure of vitamin transport inside the nervous system.
Subject of Research: Autoantibodies against the transcobalamin receptor CD320 in idiopathic myelopathy and central nervous system-restricted vitamin B12 deficiency.
Web References: https://doi.org/10.1001/jamaneurol.2026.2778
References: JAMA Neurology study identified by DOI 10.1001/jamaneurol.2026.2778.
Keywords: idiopathic myelopathy, CD320, transcobalamin receptor, vitamin B12, cobalamin deficiency, subacute combined degeneration, autoantibodies, autoimmune neurology, spinal cord disease, central nervous system metabolism
Tags: Autoantibodies against CD320 in myelopathyautoimmune contribution to spinal cord diseasesautoimmune neurological disordersB12 metabolism and nervous systemdiagnostic challenges in myelopathyidiopathic myelopathyimmune response in nerve damageneurological biomarkersSpinal Cord Injurysubacute combined degenerationvitamin B12 deficiencyvitamin B12 transport system
